EUCTR2006-006047-30-IT进行中（未招募）1 期
First line treatment in HIV-related diffuse large cell non Hodgkin Lymphoma at ''high risk'', including early consolidation with high dose chemotherapy and autologous peripheral blood stem cell transplantation - ND
AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA0 个研究点开始时间: 2007年11月12日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-age<61years -LNH HIV related -IPI: 2-3 -stage IB-IV
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-LNH Burkitt or Lymphoblastic -IPI: 0-1 -cardiac, respiratory, hepatic, renal failure -bone marrow failure -lymphoma localized at SNC
研究者
相似试验
已完成
2 期
High Dose Therapy and Peripheral Blood Stem Cell Transplantation in HIV Related Non Hodgkin Lymphoma (NHL) at High RiskHIV-related LymphomaHIV InfectionsNCT01045889Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia27
进行中（未招募）
不适用
Active immunotherapy against HIV during highly active anti-retroviral therapy followed by repeated treatment interruptions, VAC 09. - Vac 09Treatment of HIV infectionEUCTR2005-002849-40-SESwedish Institute for Infectious Disease Control30
进行中（未招募）
1 期
A study of the effect of antiretroviral therapy and immunoglobulin on the HIV reservoir in Acute HIV Infection.Acute HIV InfectionMedDRA version: 14.1 Level: LLT Classification code 10000811 Term: Acute infection with HIV System Organ Class: 10021881 - Infections and infestationsEUCTR2011-001982-42-GBGuy's & St. Thomas' NHS Foundation Trust10
进行中（未招募）
1 期
Initiation of first-line antiretroviral treatment with TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the first clinical contact in France: Trial IMEA 055 – FASTHIV positive age > 18 years -newly diagnosed HIV-infected individual evidenced by any tests -antiretroviral-treatment naive -negative urine pregnancy test -willing to sign an informed written consent– -regular health insurance -willing to provide two distinct contact information (telephone number and/or email) in order to be easily reached if needed between Day 0 and Day 7EUCTR2019-000812-27-FRIMEA110
已完成
不适用
Highly active anti-retroviral therapy including nevirapine once daily versus twice daily after at least 12 weeks of nevirapine twice daily. A randomized, open, multicentre trial.ISRCTN81305260Institute of Biomedical Investigations of Bellvitge (Institut d'Investigació Biomèdica de Bellvitge) (IDIBELL) (Spain)308